Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

PURPOSE: Programmed death 1 is an immune checkpoint that suppresses antitumor immunity. Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkpoint inhibitor antibody, was active and generally well tolerated in patients with advanced solid tumors treated in a phase I trial with e...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:J Clin Oncol
المؤلفون الرئيسيون: Gettinger, Scott N., Horn, Leora, Gandhi, Leena, Spigel, David R., Antonia, Scott J., Rizvi, Naiyer A., Powderly, John D., Heist, Rebecca S., Carvajal, Richard D., Jackman, David M., Sequist, Lecia V., Smith, David C., Leming, Philip, Carbone, David P., Pinder-Schenck, Mary C., Topalian, Suzanne L., Hodi, F. Stephen, Sosman, Jeffrey A., Sznol, Mario, McDermott, David F., Pardoll, Drew M., Sankar, Vindira, Ahlers, Christoph M., Salvati, Mark, Wigginton, Jon M., Hellmann, Matthew D., Kollia, Georgia D., Gupta, Ashok K., Brahmer, Julie R.
التنسيق: Artigo
اللغة:Inglês
منشور في: American Society of Clinical Oncology 2015
الموضوعات:
ORIGINAL REPORTS
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC4672027/
https://ncbi.nlm.nih.gov/pubmed/25897158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.58.3708
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة